New study highlights risks of anti-ERBB2 cancer drugs during pregnancy

Australia News News

New study highlights risks of anti-ERBB2 cancer drugs during pregnancy
Australia Latest News,Australia Headlines
  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 53 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 24%
  • Publisher: 71%

Study finds that anti-ERBB2 inhibitors used in breast cancer treatment pose significant risks to pregnancy and fetal health, including higher likelihoods of congenital defects and intrauterine growth restriction.

By Dr. Liji Thomas, MDOct 29 2023Reviewed by Benedette Cuffari, M.Sc. While the treatment of breast cancer does not change with pregnancy status unless absolutely necessary, the health of the fetus must be carefully considered while deciding on the choice of therapy.

Nevertheless, breast tumors that are ERBB2-positive and hormone receptor-negative are primarily treated with anti-ERBB2 agents as a result of their historical efficacy. Since the use of these agents in pregnancy is dependent on the expectation of greater maternal benefit as compared to fetal harm, extensive studies are required to confirm their safety during pregnancy.

The mean participant age in the anti-ERBB2 group was about 31 years, with nearly half of patients from the United States. Most were being treated for breast cancer. The most commonly used drug was trastuzumab, with about 20 each receiving trastuzumab-emtansine or lapatinib, while 55 were on pertuzumab.

Oligohydramnios were reported in about 25% of exposures, whereas preterm birth was reported in over one in seven cases. Intrauterine growth restriction was reported in 10% of cases. Fetal kidney failure, leading to oligohydramnios, and subsequently to pulmonary hypoplasia and neonatal respiratory disorders, has been described in a Potter sequence.”

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NewsMedical /  🏆 19. in UK

Australia Latest News, Australia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Silverburn Reveals New Restaurant Opening and Five New StoresSilverburn Reveals New Restaurant Opening and Five New StoresThe Silverburn boss has revealed details behind their latest restaurant opening and five new stores. The centre is helping visitors prepare for Christmas with new offerings for eating, drinking and shopping.
Read more »

Silverburn Reveals New Restaurant and Five New StoresSilverburn Reveals New Restaurant and Five New StoresSilverburn shopping centre has announced the opening of a new restaurant and five new stores, just in time for Christmas. Eyewear brand Pop Specs has opened a permanent kiosk, while Calender Club has launched a pop-up. Menkind and BPerfect are also set to open soon. In addition, burger eatery Bread Meats Bread has replaced pancake restaurant Stack and Still. Existing stores Hobbs, Next, and Zizzi have also undergone makeovers. David Pierotti, General Manager of Silverburn, expressed the centre's commitment to providing a top-notch retail and leisure experience.
Read more »

Cyclists are more caring over range of issues affecting their communities than drivers, study findsCyclists are more caring over range of issues affecting their communities than drivers, study findsStudy: Cyclists more caring than drivers on community issues
Read more »

Study offers the most comprehensive look to date on prostate cancer disparitiesStudy offers the most comprehensive look to date on prostate cancer disparitiesCedars-Sinai Cancer investigators have found that Black men respond as well as white men to systemic therapies for advanced prostate cancer when access to quality healthcare is equal, regardless of socioeconomic status.
Read more »

Big increase in over 65-year-olds in work, study suggestsBig increase in over 65-year-olds in work, study suggestsWorking beyond state pension age is becoming increasingly common, a report has found.
Read more »



Render Time: 2025-02-26 13:23:25